Reviva Pharmaceuticals Holdings, Inc. Sale of Stock, Consideration Received on Transaction
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Sale of Stock, Consideration Received on Transaction of $56.10 million for the 9-month period ending 2019-11-30, per its 10-Q filed 2020-01-10.
Discontinued › Notes
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2021-01-14
- 2019-11-30: Sale of Stock, Consideration Received on Transaction 9 month $56.10M.
- 2018-08-30: Sale of Stock, Consideration Received on Transaction $8.41M; Sale of Stock, Consideration Received on Transaction 1 month $8.41M.
- 2018-08-23: Sale of Stock, Consideration Received on Transaction $56.10M; Sale of Stock, Consideration Received on Transaction 1 month $56.10M.
| Period end | Sale of Stock, Consideration Received on Transaction | Sale of Stock, Consideration Received on Transaction 1 month | Sale of Stock, Consideration Received on Transaction 9 month |
|---|---|---|---|
| 2019-11-30 | $56.10M 10-Q · filed 2020-01-10 | ||
| 2018-08-30 | $8.41M 10-Q · filed 2021-01-14 | $8.41M 10-Q · filed 2019-07-03 | |
| 2018-08-23 | $56.10M 10-Q · filed 2019-10-08 | $56.10M 10-Q · filed 2019-07-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |